Tiagabine hydrochloride

Base Information

• Chemical Name: Tiagabine hydrochloride
• CAS No.: 145821-59-6
• Molecular Formula: C20H25NO2S2.HCl
• Molecular Weight: 412.01
• UNII: DQH6T6D8OY
• DSSTox Substance ID: DTXSID2044218
• Wikidata: Q27158534
• NCI Thesaurus Code: C47755
• RXCUI: 236875
• Pharos Ligand ID: KWXTL21QA8XP
• ChEMBL ID: CHEMBL1695
• Mol file: 145821-59-6.mol

Synonyms:(R)-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, hydrochloride;Gabitril;N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid;NO 328;NO 329;NO-328;NO-329;tiagabine;Tiagabine Hydrochloride;tiagabine, (S)-isomer

Chemical Property of Tiagabine hydrochloride

Chemical Property:

• Appearance/Colour: White to off-white solid
• Vapor Pressure: 9.71E-14mmHg at 25°C
• Melting Point: >192oC dec.
• Boiling Point: 568 °C at 760 mmHg
• PKA: pKa1 3.3; pKa2 9.4(at 25℃)
• Flash Point: 297.3 °C
• PSA: 97.02000
• LogP: 5.78470
• Storage Temp.: -20°C Freezer
• Solubility.: H2O: soluble10mg/mL, clear
• Hydrogen Bond Donor Count: 2
• Hydrogen Bond Acceptor Count: 5
• Rotatable Bond Count: 6
• Exact Mass: 411.1093491
• Heavy Atom Count: 26
• Complexity: 474

Purity/Quality:

98%,99%, ^*data from raw suppliers

Tiagabine, Hydrochloride ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn
• Hazard Codes: Xn,T,F
• Statements: 20/21/22-39/23/24/25-23/24/25-11
• Safety Statements: 36/37-45-16-7

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CC1=C(SC=C1)C(=CCCN2CCCC(C2)C(=O)O)C3=C(C=CS3)C.Cl
• Isomeric SMILES: CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C.Cl
• Recent ClinicalTrials: Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
• Indications: Tiagabine is licensed by the United States Food and Drug Administration (FDA) for adjunctive therapy in adults, and children of 12 years and older in the treatment of partial seizures with or without secondary generalization. There is no evidence to support a broader spectrum of action in epilepsy (Ben-Menachem 1995; Bialer et al. 2007). Tiagabine is also licensed in Europe by the European Medicines Agency (EMEA) for the same indications.
• Drug Interactions: Tiagabine has minimal potential interaction with other drugs (Leppik et al. 1999). Tiagabine is not known to cause either induction or inhibition of hepatic microsomal enzyme systems. Consequently tiagabine does not alter the plasma concentrations of other drugs including antiepileptic drugs that undergo hepatic metabolism (Gustavson et al. 1998a, b). However, enzyme-inducing drugs accelerate the hepatic metabolism of tiagabine (So et al. 1995). There is no clinically relevant interaction between tiagabine and digoxin (Snel et al. 1998).
• Description: Tiagabine (145821-59-6) is a clinically useful anticonvulsant.1?It is also used to treat anxiety/panic disorder2?and neuropathic pain3. Tiagabine inhibits GABA-reuptake (IC50?[3H]GABA uptake = 67 nM)?via?inhibiting GABA transporter 1(GAT1) blocking both neuronal and glial GABA re-uptake.4,5
• Uses: Tiagabine Hydrochloride is a GABA uptake inhibitor and an anticonvulsant (1,2,3). It is used to treat epilepsy, anxiety disorders, and panic disorder. Neuroprotective & Neuroresearch Product. Tiagabine hydrochloride was used to study serotoninergic transmission in G1 cells. It has also been used to study its anti-aging effects on the sensory neurons of C. elegans. A GABA uptake inhibitor. Anticonvulsant.
• Therapeutic Function: Antiepileptic